AI Tele-Oncology Radiation Dose Scheduler Market Report 2026

The artificial intelligence (AI) tele-oncology radiation dose scheduler market size has grown expoentially in recent years. It will grow from $0.81 billion in 2025 to $0.99 billion in 2026 at a compound annual growth rate (CAGR) of 23.3%. The growth in the historic period can be attributed to increasing need for remote cancer treatment planning, rising adoption of tele-oncology platforms, growing demand for precise radiation dose calculation, increasing use of ai in oncology decision support, rising cancer incidence worldwide, growing digital transformation in hospitals, increasing deployment of cloud-based medical systems, rising need for workflow automation in radiotherapy, growing focus on reducing treatment errors, increasing adoption of smart oncology scheduling tools.

The artificial intelligence (AI) tele-oncology radiation dose scheduler market size is expected to see exponential growth in the next few years. It will grow to $2.28 billion in 2030 at a compound annual growth rate (CAGR) of 23%. The growth in the forecast period can be attributed to expansion of tele-oncology networks, adoption of ai-enabled treatment planning platforms, rising demand for automated dose calculation systems, uptake of cloud-based oncology scheduling modules, deployment of predictive oncology algorithms, development of remote radiotherapy review tools, demand for precision-based cancer care, integration of ai tools into oncology departments, partnerships between ai vendors and cancer centers, growing acceptance of tele-radiation workflows. Major trends in the forecast period include advancement in ai-driven radiotherapy dose prediction, advancement in cloud-based oncology scheduling platforms, advancement in real-time dose optimization engines, innovation in automated treatment planning systems, innovation in predictive oncology algorithms, innovation in virtual radiation oncology workflows, integration of tele-oncology with hospital info systems, integration of ai dose schedulers with imaging platforms, integration of remote dose-review tools for oncologists, integration of multi-center tele-radiation networks.

The rising prevalence of cancer is expected to propel the growth of the artificial intelligence (AI) tele-oncology radiation dose scheduler market going forward. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells that can damage surrounding tissues and organs if not treated effectively. The prevalence of cancer is increasing due to lifestyle-related risks such as poor diet, smoking, alcohol consumption, and exposure to environmental pollutants, elevating the risk of developing various cancers. Artificial intelligence (AI) tele-oncology radiation dose schedulers support cancer management by optimizing and personalizing radiation treatment plans through remote, data-driven analysis. They improve patient outcomes by ensuring accurate dosing, reducing treatment delays, and enabling consistent care across locations. For instance, in October 2025, according to NHS Digital, a UK government organisation, there were 354,820 new cancer diagnoses recorded in England in 2023, averaging 972 diagnoses per day and representing an increase of 8,605 cases compared to 2022, with prostate cancer being the most commonly diagnosed at 58,137 new cases, reflecting a 6% increase in registrations compared to the previous year. Therefore, the rising prevalence of cancer is driving the growth of the artificial intelligence (AI) tele-oncology radiation dose scheduler market.

Key players operating in the AI tele‑oncology and radiation therapy market are focusing on developing advanced solutions, such as AI-powered dose prediction, to predict personalized radiation dose distributions and improve treatment planning efficiency. AI-powered dose prediction platforms are software solutions used to analyze imaging and anatomical data, generate clinically achievable 3D dose distributions, and support timely adjustments to optimize therapy. For instance, in March 2025, MVision AI, a Finland-based health‑tech company, launched Dose+. This AI-powered dose prediction platform incorporates specialized models for prostate and pelvic lymph node cases, tailors dose distributions to each patient’s anatomy, and supports integration with standard treatment planning systems via DICOM to facilitate efficient planning workflows. This launch represents a significant technological advancement by integrating AI-driven dose prediction into routine clinical practice, bridging traditional planning with automated, patient-specific optimization, and providing clinicians with a scalable, efficient solution for precise, personalized radiation therapy.

In October 2024, Baylor College of Medicine, a US-based academic health science center, partnered with mVIZION.ai Inc. to advance AI innovations in radiation therapy planning and delivery. Through this collaboration, Baylor College of Medicine and mVIZION.ai aim to develop and refine AI-powered radiation dose scheduling and optimization tools that support personalized treatment regimens, reduce variability in therapy delivery, and improve clinical outcomes in oncology care. mVIZION.ai Inc. is a US-based artificial intelligence healthcare company.

Major companies operating in the artificial intelligence (AI) tele-oncology radiation dose scheduler market are IBM Corporation, Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Varian Medical Systems Inc., Elekta AB, Shanghai United Imaging Healthcare Co. Ltd., Accuray Incorporated, Brainlab AG, RaySearch Laboratories AB, MIM Software Inc., Sun Nuclear Corp., DeepHealth, Radformation Inc., MVision AI Ltd., Mirada Medical Ltd., ViewRay Inc., Oncora Medical, Enlitic, Optellum Ltd.

North America was the largest region in the AI tele-oncology radiation dose scheduler market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) tele-oncology radiation dose scheduler market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI) tele-oncology radiation dose scheduler market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have affected the ai tele-oncology radiation dose scheduler market by increasing the cost of importing ai-optimized servers, edge computing devices, and specialized radiotherapy hardware. this has slowed deployment in regions dependent on imported equipment, particularly in asia-pacific and latin america. segments such as hardware and ai software services are most impacted, while cloud-based deployment and remote consultation services may benefit from local alternatives. overall, tariffs have pushed manufacturers to explore localized production and diversified sourcing strategies to maintain market growth.

An artificial intelligence (AI) tele-oncology radiation dose scheduler is a digital system that uses AI to assist clinicians in planning, adjusting, and optimizing radiation dose schedules remotely. It analyzes clinical, imaging, and treatment data to provide patient-specific dosing recommendations. This technology enhances accuracy, reduces planning time, and supports efficient remote oncology workflows.

The primary components of AI tele-oncology radiation dose schedulers consist of software, hardware, and services. Software includes AI-enabled scheduling and planning platforms that automate dose planning, coordinate workflows, and optimize resources for remote and centralized radiation oncology operations. These systems utilize technologies such as machine learning, natural language processing, computer vision, and predictive analytics, and are deployed through on-premises, cloud-based, and hybrid models. Applications include auto-contouring and segmentation, treatment plan generation and optimization, dose prediction and quality assurance, workflow and resource scheduling, and adaptive radiotherapy planning, used by hospitals, cancer treatment centers, research institutions, and others.

The artificial intelligence (AI) tele-oncology radiation dose scheduler market consists of revenues earned by entities by providing services such as remote radiation dose planning services, AI-driven treatment scheduling, tele-consultation support for oncology dosing, cloud-based radiation planning assistance and real-time dose adjustment analytics. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI) tele-oncology radiation dose scheduler market consists of sales of AI radiation planning software, tele-oncology workflow platforms, cloud-based dose scheduling tools, automated treatment optimization algorithms, and radiation dose calculation systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.